1.
J Asthma Allergy
; 13: 505-508, 2020.
Article
in English
| MEDLINE | ID: covidwho-883772
ABSTRACT
There have recently been major objections to the use of short-acting beta-agonist (SABA) in episodic acute asthma culminating in a call for replacing SABA with combination of inhaled corticosteroids and long-acting beta-agonists despite little evidence supporting this point of view. It is regrettable to note that this attack on SABA occurs in the midst of an unprecedented demand for, and shortage of, SABA inhalers during the current COVID-19 pandemic, and the worldwide efforts to increase SABA supplies. In this commentary, we defend the well-established role of SABA and argue that the call for the phase out of SABA is inappropriate, since it is not solidly evidence based.
2.
J Allergy Clin Immunol
; 146(2): 331, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-622977
Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Equipment Design/instrumentation , Metered Dose Inhalers/virology , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Administration, Inhalation , Albuterol/therapeutic use , Asthma/drug therapy , Bronchodilator Agents/therapeutic use , COVID-19 , Coronavirus Infections/transmission , Coronavirus Infections/virology , Humans , Metered Dose Inhalers/economics , Pneumonia, Viral/transmission , Pneumonia, Viral/virology , Pulmonary Disease, Chronic Obstructive/drug therapy , Risk , SARS-CoV-2
3.
CMAJ
; 192(13): E346, 2020 03 30.
Article
in English
| MEDLINE | ID: covidwho-124882